Residual inflammatory risk and the plaque immune microenvironment in coronary artery disease: evidence and limits of precision immunotherapy

Cardiovascular events persist despite lipid-lowering therapy, motivating interventions against the inflammatory component of residual risk. The translational challenge is to distinguish prognostic biomarkers, causal pathways and treatment-responsive immune states. This narrative review links clinical trials with plaque biology and human single-cell and spatial studies to assess precision immunotherapy in coronary artery disease (CAD). CANTOS, COLCOT and LoDoCo2 demonstrated benefit in specific populations, whereas CIRT and CLEAR SYNERGY were neutral. Ziltivekimab lowered inflammatory biomarkers in RESCUE, while the sponsor-reported neutral ZEUS topline result underscores the need for cardiovascular outcomes. Low-dose IL-2 expanded regulatory T cells in the phase 2 IVORY imaging trial. Within plaques, retained and oxidized lipoproteins engage innate immune pathways alongside metabolic stress and diverse vascular and immune-cell states. Human datasets localize macrophage niches, microvascular interfaces and adaptive immunity, while experimental models test candidate functions. Most tissue evidence comes from carotid lesions or animal models. We evaluate IL-1β/NLRP3, IL-6 and macrophage-state pathways, then identify requirements for matching targets to patients, including plaque-focused biomarkers, coronary-relevant validation, functional perturbation and prospective trials that measure cardiovascular benefit and immune safety.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fcvm.2026.1989977
Primary Topic
Atherosclerosis and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Residual inflammatory risk and the plaque immune microenvironment in coronary artery disease: evidence and limits of precision immunotherapy

Yueqing Han, Shaoyang Men, Xianqin Tang, Yunting Lu
Frontiers in Cardiovascular Medicine
Atherosclerosis and Cardiovascular Diseases
article

Residual inflammatory risk and the plaque immune microenvironment in coronary artery disease: evidence and limits of precision immunotherapy

Yueqing Han, Shaoyang Men, Xianqin Tang, Yunting Lu
article en

Abstract

Cardiovascular events persist despite lipid-lowering therapy, motivating interventions against the inflammatory component of residual risk. The translational challenge is to distinguish prognostic biomarkers, causal pathways and treatment-responsive immune states. This narrative review links clinical trials with plaque biology and human single-cell and spatial studies to assess precision immunotherapy in coronary artery disease (CAD). CANTOS, COLCOT and LoDoCo2 demonstrated benefit in specific populations, whereas CIRT and CLEAR SYNERGY were neutral. Ziltivekimab lowered inflammatory biomarkers in RESCUE, while the sponsor-reported neutral ZEUS topline result underscores the need for cardiovascular outcomes. Low-dose IL-2 expanded regulatory T cells in the phase 2 IVORY imaging trial. Within plaques, retained and oxidized lipoproteins engage innate immune pathways alongside metabolic stress and diverse vascular and immune-cell states. Human datasets localize macrophage niches, microvascular interfaces and adaptive immunity, while experimental models test candidate functions. Most tissue evidence comes from carotid lesions or animal models. We evaluate IL-1β/NLRP3, IL-6 and macrophage-state pathways, then identify requirements for matching targets to patients, including plaque-focused biomarkers, coronary-relevant validation, functional perturbation and prospective trials that measure cardiovascular benefit and immune safety.

Frontiers in Cardiovascular MedicineVol. 13
Guangzhou University of Chinese Medicine (CN)
National Natural Science Foundation of China, Guangzhou University of Chinese Medicine
Good health and well-being
Atherosclerosis and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon